Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose?
- 24 May 2006
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 33 (S1) , 38-43
- https://doi.org/10.1007/s00259-006-0134-2
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Positron-Emission Tomography and Assessment of Cancer TherapyNew England Journal of Medicine, 2006
- Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomographyNuclear Medicine and Biology, 2004
- Imaging of esophageal and gastric cancerSeminars in Oncology, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Nucleotide and Nucleoside Analogues as Inhibitors of Cytosolic 5‘-Nucleotidase I from HeartBiochemistry, 1998
- NM23 gene expression correlates with cell growth rate and S‐phaseInternational Journal of Cancer, 1995
- Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancerBritish Journal of Surgery, 1994
- Phosphorylation, anti-HIV activity and cytotoxicity of 3′-fluorothymidineBiochemical and Biophysical Research Communications, 1988
- Transport of thymidine during the cell cycle in mitotically synchronized CHO cellsExperimental Cell Research, 1975
- Thymidine transport by Novikoff rat hepatoma cells synchronized by double hydroxyurea treatmentExperimental Cell Research, 1974